Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
Open Access
- 1 January 2011
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 17 (37), 4166-73
- https://doi.org/10.3748/wjg.v17.i37.4166
Abstract
The thiopurine drugs, 6-mercaptopurine (6-MP) and azathioprine, are efficacious in the arsenal of inflammatory bowel disease (IBD) therapy. Previous reports indicate that 6-thioguanine nucleotide (6-TGN) levels correlate with therapeutic efficacy, whereas high 6-methylmercaptopurine (6-MMP) levels are associated with hepatotoxicity and myelotoxicity. Due to their complex metabolism, there is wide individual variation in patient response therein, both in achieving therapeutic drug levels as well as in developing adverse reactions. Several strategies to optimize 6-TGN while minimizing 6-MMP levels have been adopted to administer the thiopurine class of drugs to patients who otherwise would not tolerate these drugs due to side-effects. In this report, we will review different approaches to administer the thiopurine medications, including the administration of 6-mercaptopurine in those unsuccessfully treated with azathioprine; co-administration of thiopurine with allopurinol; co-administration of thiopurine with anti-tumor necrosis factor α; 6-TGN administration; desensitization trials; and split dosing of 6-MP.Keywords
This publication has 79 references indexed in Scilit:
- Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure?Therapeutic Advances in Gastroenterology, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trialBlood, 2010
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-MercaptopurineThe American Journal of Gastroenterology, 2005
- 6‐Tioguanine monitoring in steroid‐dependent patients with inflammatory bowel diseases receiving azathioprineAlimentary Pharmacology & Therapeutics, 2005
- Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2004
- A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patientsJournal of the American Academy of Dermatology, 1995
- Effect of allopurinol on the intestinal absorption of 6-mercaptopurine in rats.Journal of Pharmacobio-Dynamics, 1987
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980